Skip to Main Content
research
nutrition
Cancer
Reporting from the frontiers of health and medicine
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Health tech
STAT+

Teladoc stock slides despite business growth, Medtronic CEO talks innovation

  • Mario Aguilar

By Mario Aguilar Oct. 26, 2023

Reprints
Unicorn Stocks
Adobe

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. 

Teladoc’s stock slides despite business growth

advertisement

Teladoc Health on Tuesday reported solid third quarter earnings showing $660 million in revenue for 8% year-over-year growth and improvement across business lines including BetterHelp and its closely watched chronic care segment.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

About the Author Reprints

Mario Aguilar

Mario Aguilar

Health Tech Correspondent

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech's promise. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter.

linkedin.com/in/mario-aguilar-13361235/

Tags

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.

FDA authorizes new drug to protect immune compromised from…
FDA authorizes new drug to protect immune compromised from Covid-19
Drug development was once a marathon. New tools and…
Drug development was once a marathon. New tools and timelines are turning it into a sprint
A study says intermittent fasting is making people drop…
A study says intermittent fasting is making people drop dead. Oh, come on
How biotech investors spot opportunity when stocks are down…
How biotech investors spot opportunity when stocks are down — and up
How a for-profit health system’s push to expand ended…
How a for-profit health system’s push to expand ended in disappointment for a tiny island nation
Despite new Wegovy coverage, Medicare patients may face high…
Despite new Wegovy coverage, Medicare patients may face high drug costs and other hurdles

Recommended Stories